Back to Search Start Over

Development of Amphotericin B Decorated Gold Nanoparticles as a Promising Antileishmanial Nanoconjugate.

Authors :
Sharma K
Shah J
Singh S
Sengupta S
Source :
ACS applied bio materials [ACS Appl Bio Mater] 2024 Sep 16; Vol. 7 (9), pp. 6239-6248. Date of Electronic Publication: 2024 Aug 18.
Publication Year :
2024

Abstract

Leishmaniasis, attributed to the protozoan parasite Leishmania , manifests in diverse clinical forms, including cutaneous, mucocutaneous, and visceral leishmaniasis; VL constitutes a significant global health menace. Prevalent in tropical and subtropical regions, this affliction disproportionately impacts individuals below the poverty threshold, transmitted through the bite of female sandflies. Existing treatments, such as pentavalent antimony, miltefosine, and Amphotericin B, exhibit limitations. Despite the emergence of liposomal Amphotericin B (AmBisome) as a promising antileishmanial agent, its utility is impeded by adverse effects, elevated production expenses, and cytotoxicity. To address these challenges, our investigation introduces a potential remedy─a citrate-coated gold Amphotericin B nanoparticle formulation. Characterized using dynamic light scattering and transmission electron microscopy, this pioneering formulation exhibited efficacy against L. donovani Ag83 promastigotes as demonstrated by MTT cell viability testing. Evaluating internal reactive oxygen species (ROS) levels and dual staining with acridine orange and ethidium bromide unveiled its consequential impact on cell death. Significantly, our study discloses this novel nanoformulation's unprecedented inhibition of the trypanothione reductase enzyme. The findings posit the citrate-coated gold Amphotericin B nanoformulation as a promising and targeted antileishmanial agent, representing potential advancements in leishmaniasis therapeutics.

Details

Language :
English
ISSN :
2576-6422
Volume :
7
Issue :
9
Database :
MEDLINE
Journal :
ACS applied bio materials
Publication Type :
Academic Journal
Accession number :
39155492
Full Text :
https://doi.org/10.1021/acsabm.4c00835